drugset
Drugs / KALLIKREIN-1
last change Jan 2019 re-read 3 minutes ago

KALLIKREIN-1

also known as Klk-1 · tissue kallikrein
Developed for
cerebrovascular disorder
Investigated by
Jinling Hospital, China

Trials 1

today NCT01558245 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01558245 Dec 2011 → Dec 2013 cerebrovascular disorder Jinling Hospital, China Unknown Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2019-01-22 DiaMedica Therapeutics Inc DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders diamedica.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as KALLIKREIN-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL4298121 ↗
Known as Klk-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL4298121 ↗
Known as tissue kallikrein ClinicalTrials.gov intervention name — accepted as the source's own label NCT01558245 ↗
Route Intravenous “Patients in tissue kallikrein treatment group will be prescribed with intravenous infusion of tissue kallikrein” PMID 24354519 ↗ Dec 2013